Legal & General Group Plc Makes New $28,000 Investment in Upstream Bio, Inc. (NASDAQ:UPB)

Legal & General Group Plc bought a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the fourth quarter, HoldingsChannel.com reports. The fund bought 1,734 shares of the company’s stock, valued at approximately $28,000.

A number of other hedge funds have also made changes to their positions in the business. Moody Aldrich Partners LLC purchased a new position in Upstream Bio in the fourth quarter valued at about $1,229,000. Rhumbline Advisers acquired a new stake in shares of Upstream Bio in the fourth quarter valued at about $275,000. Bank of New York Mellon Corp purchased a new stake in shares of Upstream Bio during the 4th quarter valued at about $607,000. US Bancorp DE acquired a new position in Upstream Bio during the 4th quarter worth approximately $27,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Upstream Bio in the 4th quarter worth approximately $2,225,000.

Upstream Bio Price Performance

UPB stock opened at $9.00 on Friday. The firm has a 50 day simple moving average of $7.94 and a 200-day simple moving average of $14.24. Upstream Bio, Inc. has a twelve month low of $5.14 and a twelve month high of $29.46.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.